about
Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the artPreparation and use of 131I magic gel as a dosimeter for targeted radionuclide therapy.Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.(18)F-Fluorine-18-l-dihydroxyphenylalanine ((18)F-DOPA) positive isolated peritoneal carcinomatosis from a MENII-related medullary thyroid carcinoma. About an atypical metastatic site and utility of (18)F-FDOPA.Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation.Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin's disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition.Breast imaging: understanding how accuracy is measured when lesion are the unit of analysis.Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study).Comparison of an alternative and existing binning methods to reduce the acquisition duration of 4D PET/CT.Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response.Evaluation of a trainer phantom in the learning phase of sentinel lymph node identification in breast cancer.Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.Oncocytic Adenoma of Thyroid Incidentally Detected by 18F-Fluorocholine PET/CT.Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases.Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer.V-Q SPECT in prone position is a suitable way to improve irradiation of inoperable lung cancer.Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine TumorsDefective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinomaThe incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancerFunctional testicular evaluation using PET/CT with 18F-fluorodeoxyglucoseEvaluation of 2 diuretic 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography imaging protocols for intrapelvic cancer
P50
Q26995317-E12D6599-4CB3-4C45-8787-6EB693F9537CQ31077001-837A1630-3797-4E4C-A2D6-D4054A6774A0Q33410236-3E4E29A3-F2D0-41ED-9F48-055E4CD1D86AQ34000333-5E5862DE-BCB1-4115-9DFE-BCC3FC976191Q35155742-7BCC8867-5648-48D4-8D1F-A7942D43820EQ38264850-EDB69D7A-8153-410D-9B75-3962AE25E258Q42522118-73CB018D-3051-4FAA-BA87-BB3280CE5C26Q42825863-7173F39F-F793-47C6-8F1F-01193F5676E3Q43669829-83E258E7-88D6-4BCD-A5D7-D06DCA23A34AQ46339184-21C32F0B-4A88-4E62-A4F7-149DB60B5622Q46477657-C6C9FBA8-A772-4D5B-AA23-24C5BAF44251Q47960840-193D5B5A-8DB3-42B2-A6C2-32F6DA6C0653Q48813476-4587C420-F3AC-405A-8A73-ACC6C1724ECFQ50526591-37320E99-B08E-4965-809E-6C970E2E32FFQ51052327-0821154C-E1EC-48EA-B3EA-EC85045ED5AFQ51177755-F3304B23-62C3-448F-A6C5-6B221669934DQ53016141-D321C11D-17EA-4155-BBBD-A96C528144C1Q53195557-BA36C574-0A36-401B-9097-14611255EDF4Q53243638-AACC4517-9369-46A6-83FF-D879E6886863Q53345317-D18F2B32-52B5-4ABA-816C-FD01F7706CCEQ53542361-C9F1F6E3-32B3-4B3E-859F-6AF49624E20BQ60727893-E475953C-E201-450B-BEA4-8A554BECBCDEQ79248730-41B9B148-150B-4CF2-8BE9-AA144F7FE9F0Q81453000-135A5A4B-7485-4CBF-B034-89D61AE90121Q84935425-0B772DAA-5D1A-4B41-A222-0CE1821EDF11Q87706010-3C45B23E-EBB6-49CF-91EA-6ADBF0E6E126
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
F Courbon
@en
F Courbon
@nl
type
label
F Courbon
@en
F Courbon
@nl
prefLabel
F Courbon
@en
F Courbon
@nl
P31
P496
0000-0002-1279-2362